128 related articles for article (PubMed ID: 23775427)
1. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.
Biesbroeck LK; Scott JD; Taraska C; Moore E; Falsey RR; Shinohara MM
Am J Clin Dermatol; 2013 Dec; 14(6):497-502. PubMed ID: 23775427
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir-induced DRESS.
Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
[TBL] [Abstract][Full Text] [Related]
3. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir-related dermatitis.
Roujeau JC; Mockenhaupt M; Tahan SR; Henshaw J; Martin EC; Harding M; van Baelen B; Bengtsson L; Singhal P; Kauffman RS; Stern RS
JAMA Dermatol; 2013 Feb; 149(2):152-8. PubMed ID: 23560295
[TBL] [Abstract][Full Text] [Related]
5. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
[TBL] [Abstract][Full Text] [Related]
6. First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
Samain A; Duval-Modeste AB; Joly P; Leblanc C; Massy N; Courville P; Goria O; Riachi G
J Hepatol; 2014 Apr; 60(4):891-3. PubMed ID: 24333861
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
8. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
9. Widespread morbilliform eruption associated with telaprevir: use of dermatologic consultation to increase tolerability.
Strazzula L; Pratt DS; Zardas J; Chung RT; Thiim M; Kroshinsky D
JAMA Dermatol; 2014 Jul; 150(7):756-9. PubMed ID: 24718650
[TBL] [Abstract][Full Text] [Related]
10. A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms.
Cengiz FP; Su O; Emiroglu N; Biyik Ozkaya D; Bahali AG; Onsun N
G Ital Dermatol Venereol; 2019 Aug; 154(4):488-491. PubMed ID: 31251007
[TBL] [Abstract][Full Text] [Related]
11. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
Beste LA; Green PK; Ioannou GN
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
[TBL] [Abstract][Full Text] [Related]
12. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
14. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
15. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
16. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Cacoub P; Bourlière M; Lübbe J; Dupin N; Buggisch P; Dusheiko G; Hézode C; Picard O; Pujol R; Segaert S; Thio B; Roujeau JC
J Hepatol; 2012 Feb; 56(2):455-63. PubMed ID: 21884670
[TBL] [Abstract][Full Text] [Related]
17. [Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection].
Martín Domínguez V; Carrascosa de Lome R; Becerro González I; de Argila D; Villar K; García-Buey L
Gastroenterol Hepatol; 2015 Oct; 38(8):491-3. PubMed ID: 25454599
[No Abstract] [Full Text] [Related]
18. Management of anaemia and other treatment complications.
Hézode C
Dig Liver Dis; 2013 Sep; 45 Suppl 5():S337-42. PubMed ID: 24091113
[TBL] [Abstract][Full Text] [Related]
19. [Boceprevir and telaprevir utilization: evaluation for the treatment of chronic hepatitis C].
Marrero-Álvarez P; Gil-Gómez I; Monte-Boquet E; Lorente-Fernández L; Poveda-Andrés JL
Farm Hosp; 2014 Jan; 38(1):30-7. PubMed ID: 24483857
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
